drugset / Trial / NCT00945763

Single Dose Study of N1539 in the Treatment of Pain Secondary to Dental Impaction Surgery

NCT00945763

Phase 2 Completed 230 enrolled Alkermes, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To evaluate the safety and efficacy of single IV doses of N1539 after dental impaction surgery.

Timeline

Start
2009-07
Primary completion
2009-11
Completion
2009-11

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ibuprofen Small molecule 400 mg Oral
Subject Meloxicam Small molecule 15 mg Intravenous
Subject Meloxicam Small molecule 30 mg Intravenous
Subject Meloxicam Small molecule 60 mg Intravenous

Indications

No indication recorded.